-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Category Archives: Endocrinology
Incretin Mimetic Drugs for Type 2 Diabetes
Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication – Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas AUDIENCE: Gastroenterology, Endocrinology, Oncology, Patient ISSUE: FDA is evaluating unpublished new findings by a group of … Continue reading
Posted in Endocrinology, FDA 2013, FDA Warning, Gastroenterology, Oncology, Patients
Tagged drug risks, Endocrinology, FDA warning, Gastroenterology, Incretin Mimetic Drugs, Incretin Mimetic Drugs for Type 2 Diabetes, Oncology, Patient, Type 2 Diabetes
Comments Off
Sensipar Cinacalcet Hydrochloride Drug Safety Communication
Sensipar (Cinacalcet Hydrochloride): Drug Safety Communication – FDA Suspends Pediatric Clinical Trials After Report Of Death AUDIENCE: Health Professional, Endocrinology, Pediatrics ISSUE: FDA has stopped all pediatric clinical trials of Sensipar (cinacalcet hydrochloride) after the recent death of … Continue reading
Posted in Clinical Trials, Endocrinology, FDA 2013, FDA Safety Communication, Healthcare Professionals, Pediatrics
Tagged 14 year old death, chronic kidney disease, Cinacalcet Hydrochloride, Clinical Trials, drug risks, Drug Safety Communication, FDA recall, Sensipar, Sensipar Cinacalcet Hydrochloride Drug Safety Communication
Comments Off
Aliskiren containing Medications Drug Safety Comunication
Aliskiren-containing Medications: Drug Safety Comunication – New Warning and Contraindication including: Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide) Tekturna (aliskiren hemifumarate) Tekturna HCT (aliskiren hemifumarate and hydrochlorothiazide) Tekamlo (aliskiren hemifumarate and amlodipine besylate) Valturna (aliskiren hemifumarate and valsartan). Valturna will … Continue reading
Posted in Endocrinology, FDA 2012, FDA Safety Communication, Internal Medicine, Pharmacy
Tagged Aliskiren containing Medications, aliskiren hemifumarate, aliskiren hemifumarate and amlodipine besylate, aliskiren hemifumarate and hydrochlorothiazide, aliskiren hemifumarate and valsartan, amlodipine besylate, Amturnide, and hydrochlorothiazide, Drug Safety Communication, Endocrinology, fda, Internal Medicine, Pharmacy, Tekamlo, Tekturna, Tekturna HCT, Valturna
Comments Off
Is Avandia Worth The Risk?
Is Avandia Worth The Risk? There has been several reported deaths from Avandia from heart attacks and strokes but meanwhile the FDA has refused to recall it. they have only recently updated their warnings about the increased risks to patients. … Continue reading
Posted in Avandia, Endocrinology, FDA 2011, FDA Warning
Tagged adverse, Avandia, Avandia(rosiglitazone), benefits, diabetes, drug, drug risks, effects, fda, FDA warning, lawsuits, Risks, safety label changes, side effects and risk of Avandia, type 2
Comments Off
Reclast zoledronic acid
Reclast (zoledronic acid): Drug Safety Communication – New Contraindication and Updated Warning on Kidney Impairment AUDIENCE: Endocrinology, Pharmacy, Patient ISSUE: FDA notified healthcare professionals and patients of an update to the drug label for Reclast (zoledronic acid) regarding the risk … Continue reading
Posted in Endocrinology, FDA 2011, Pharmacy
Tagged Drug Safety Communication, Endocrinology, FDA notice, FDA warning, Patient, Pharmacy
Comments Off